Rationale for Delayed-Start Study of Pramipexole in Parkinson's Disease: The PROUD Study
Identifieur interne : 000956 ( PascalFrancis/Corpus ); précédent : 000955; suivant : 000957Rationale for Delayed-Start Study of Pramipexole in Parkinson's Disease: The PROUD Study
Auteurs : Anthony H. V. Schapira ; Stefan Albrecht ; Paolo Barone ; Cynthia L. Comella ; Michael P. Mcdermott ; Yoshikuni Mizuno ; Werner Poewe ; Olivier Rascol ; Kenneth MarekSource :
- Movement disorders [ 0885-3185 ] ; 2010.
Descripteurs français
- Pascal (Inist)
English descriptors
Abstract
Perhaps the most important unmet need in Parkinson's disease (PD) is the ability to slow or prevent progression of the neurodegeneration that underlies the motor and nonmotor features of this disorder. Pramipexole, a dopamine agonist used for the symptomatic treatment of PD, has demonstrated neuroprotective properties in laboratory studies. The PRamipexole On Underlying Disease (PROUD) study is a randomized, double-blind clinical trial evaluating the ability of pramipexole to modify disease progression using a delayed-start design. PD patients (n = 535) with mean age 62.5 years, mean duration since diagnosis of 4.4 months, and mean total Unified Parkinson's disease Rating Scale (UPDRS) score of 24.5 were recruited. In Phase I, patients were randomly assigned to be titrated to 1.5 mg pramipexole or placebo and maintained on study drug for 6-9 months. In Phase II, all patients were titrated to 1.5 mg pramipexole and maintained on study drug until the end of the study at 15 months. No rescue medication was allowed in the protocol. The primary endpoint is the change in total UPDRS score (parts I-III) from baseline to 15 months. A range of secondary endpoints separately assess UPDRS subscales, quality of life, depression, and impulse control disorders. A sub-study examined dopamine transporter uptake scans at baseline and 15 months. The results of PROUD will provide insight into the potential for early versus delayed treatment with pramipexole to modify motor outcome at 15 months in recently diagnosed PD patients.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
| pA |
|
|---|
Format Inist (serveur)
| NO : | PASCAL 10-0413282 INIST |
|---|---|
| ET : | Rationale for Delayed-Start Study of Pramipexole in Parkinson's Disease: The PROUD Study |
| AU : | SCHAPIRA (Anthony H. V.); ALBRECHT (Stefan); BARONE (Paolo); COMELLA (Cynthia L.); MCDERMOTT (Michael P.); MIZUNO (Yoshikuni); POEWE (Werner); RASCOL (Olivier); MAREK (Kenneth) |
| AF : | Department of Clinical Neurosciences, Institute of Neurology, University College London/London/Royaume-Uni (1 aut.); Boehringer Ingelheim GmbH, CD Medical Affairs CNS/Ingelheim/Allemagne (2 aut.); Department of Neurological Sciences, University of Naples, Federico II and IDC-Hermitage-Capodimonte/Naples/Italie (3 aut.); Department of Neurological Sciences, Rush University Medical Center/Chicago, Illinois/Etats-Unis (4 aut.); Department of Biostatistics and Computational Biology, University of Rochester Medical Center/Rochester, New York/Etats-Unis (5 aut.); Department of Neurology, Juntendo University School of Medicine/Bunkyo-ku, Tokyo/Japon (6 aut.); Department of Neurology, Innsbruck Medical University/Innsbruck/Autriche (7 aut.); Departments of Clinical Pharmacology and Neurosciences, Clinical Investigation Center INSERM CIC9302 and INSERM UMR825, Toulouse University Hospital/Toulouse/France (8 aut.); Institute for Neurodegenerative Disorders/New Haven, Connecticut/Etats-Unis (9 aut.) |
| DT : | Publication en série; Niveau analytique |
| SO : | Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2010; Vol. 25; No. 11; Pp. 1627-1632; Bibl. 33 ref. |
| LA : | Anglais |
| EA : | Perhaps the most important unmet need in Parkinson's disease (PD) is the ability to slow or prevent progression of the neurodegeneration that underlies the motor and nonmotor features of this disorder. Pramipexole, a dopamine agonist used for the symptomatic treatment of PD, has demonstrated neuroprotective properties in laboratory studies. The PRamipexole On Underlying Disease (PROUD) study is a randomized, double-blind clinical trial evaluating the ability of pramipexole to modify disease progression using a delayed-start design. PD patients (n = 535) with mean age 62.5 years, mean duration since diagnosis of 4.4 months, and mean total Unified Parkinson's disease Rating Scale (UPDRS) score of 24.5 were recruited. In Phase I, patients were randomly assigned to be titrated to 1.5 mg pramipexole or placebo and maintained on study drug for 6-9 months. In Phase II, all patients were titrated to 1.5 mg pramipexole and maintained on study drug until the end of the study at 15 months. No rescue medication was allowed in the protocol. The primary endpoint is the change in total UPDRS score (parts I-III) from baseline to 15 months. A range of secondary endpoints separately assess UPDRS subscales, quality of life, depression, and impulse control disorders. A sub-study examined dopamine transporter uptake scans at baseline and 15 months. The results of PROUD will provide insight into the potential for early versus delayed treatment with pramipexole to modify motor outcome at 15 months in recently diagnosed PD patients. |
| CC : | 002B17; 002B17G |
| FD : | Maladie de Parkinson; Pathologie du système nerveux; Pramipexole |
| FG : | Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central |
| ED : | Parkinson disease; Nervous system diseases; Pramipexole |
| EG : | Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease |
| SD : | Parkinson enfermedad; Sistema nervioso patología; Pramipexol |
| LO : | INIST-20953.354000192608100140 |
| ID : | 10-0413282 |
Links to Exploration step
Pascal:10-0413282Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Rationale for Delayed-Start Study of Pramipexole in Parkinson's Disease: The PROUD Study</title><author><name sortKey="Schapira, Anthony H V" sort="Schapira, Anthony H V" uniqKey="Schapira A" first="Anthony H. V." last="Schapira">Anthony H. V. Schapira</name><affiliation><inist:fA14 i1="01"><s1>Department of Clinical Neurosciences, Institute of Neurology, University College London</s1><s2>London</s2><s3>GBR</s3><sZ>1 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Albrecht, Stefan" sort="Albrecht, Stefan" uniqKey="Albrecht S" first="Stefan" last="Albrecht">Stefan Albrecht</name><affiliation><inist:fA14 i1="02"><s1>Boehringer Ingelheim GmbH, CD Medical Affairs CNS</s1><s2>Ingelheim</s2><s3>DEU</s3><sZ>2 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Barone, Paolo" sort="Barone, Paolo" uniqKey="Barone P" first="Paolo" last="Barone">Paolo Barone</name><affiliation><inist:fA14 i1="03"><s1>Department of Neurological Sciences, University of Naples, Federico II and IDC-Hermitage-Capodimonte</s1><s2>Naples</s2><s3>ITA</s3><sZ>3 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Comella, Cynthia L" sort="Comella, Cynthia L" uniqKey="Comella C" first="Cynthia L." last="Comella">Cynthia L. Comella</name><affiliation><inist:fA14 i1="04"><s1>Department of Neurological Sciences, Rush University Medical Center</s1><s2>Chicago, Illinois</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Mcdermott, Michael P" sort="Mcdermott, Michael P" uniqKey="Mcdermott M" first="Michael P." last="Mcdermott">Michael P. Mcdermott</name><affiliation><inist:fA14 i1="05"><s1>Department of Biostatistics and Computational Biology, University of Rochester Medical Center</s1><s2>Rochester, New York</s2><s3>USA</s3><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Mizuno, Yoshikuni" sort="Mizuno, Yoshikuni" uniqKey="Mizuno Y" first="Yoshikuni" last="Mizuno">Yoshikuni Mizuno</name><affiliation><inist:fA14 i1="06"><s1>Department of Neurology, Juntendo University School of Medicine</s1><s2>Bunkyo-ku, Tokyo</s2><s3>JPN</s3><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><inist:fA14 i1="07"><s1>Department of Neurology, Innsbruck Medical University</s1><s2>Innsbruck</s2><s3>AUT</s3><sZ>7 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><inist:fA14 i1="08"><s1>Departments of Clinical Pharmacology and Neurosciences, Clinical Investigation Center INSERM CIC9302 and INSERM UMR825, Toulouse University Hospital</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Marek, Kenneth" sort="Marek, Kenneth" uniqKey="Marek K" first="Kenneth" last="Marek">Kenneth Marek</name><affiliation><inist:fA14 i1="09"><s1>Institute for Neurodegenerative Disorders</s1><s2>New Haven, Connecticut</s2><s3>USA</s3><sZ>9 aut.</sZ></inist:fA14></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">10-0413282</idno><date when="2010">2010</date><idno type="stanalyst">PASCAL 10-0413282 INIST</idno><idno type="RBID">Pascal:10-0413282</idno><idno type="wicri:Area/PascalFrancis/Corpus">000956</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Rationale for Delayed-Start Study of Pramipexole in Parkinson's Disease: The PROUD Study</title><author><name sortKey="Schapira, Anthony H V" sort="Schapira, Anthony H V" uniqKey="Schapira A" first="Anthony H. V." last="Schapira">Anthony H. V. Schapira</name><affiliation><inist:fA14 i1="01"><s1>Department of Clinical Neurosciences, Institute of Neurology, University College London</s1><s2>London</s2><s3>GBR</s3><sZ>1 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Albrecht, Stefan" sort="Albrecht, Stefan" uniqKey="Albrecht S" first="Stefan" last="Albrecht">Stefan Albrecht</name><affiliation><inist:fA14 i1="02"><s1>Boehringer Ingelheim GmbH, CD Medical Affairs CNS</s1><s2>Ingelheim</s2><s3>DEU</s3><sZ>2 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Barone, Paolo" sort="Barone, Paolo" uniqKey="Barone P" first="Paolo" last="Barone">Paolo Barone</name><affiliation><inist:fA14 i1="03"><s1>Department of Neurological Sciences, University of Naples, Federico II and IDC-Hermitage-Capodimonte</s1><s2>Naples</s2><s3>ITA</s3><sZ>3 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Comella, Cynthia L" sort="Comella, Cynthia L" uniqKey="Comella C" first="Cynthia L." last="Comella">Cynthia L. Comella</name><affiliation><inist:fA14 i1="04"><s1>Department of Neurological Sciences, Rush University Medical Center</s1><s2>Chicago, Illinois</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Mcdermott, Michael P" sort="Mcdermott, Michael P" uniqKey="Mcdermott M" first="Michael P." last="Mcdermott">Michael P. Mcdermott</name><affiliation><inist:fA14 i1="05"><s1>Department of Biostatistics and Computational Biology, University of Rochester Medical Center</s1><s2>Rochester, New York</s2><s3>USA</s3><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Mizuno, Yoshikuni" sort="Mizuno, Yoshikuni" uniqKey="Mizuno Y" first="Yoshikuni" last="Mizuno">Yoshikuni Mizuno</name><affiliation><inist:fA14 i1="06"><s1>Department of Neurology, Juntendo University School of Medicine</s1><s2>Bunkyo-ku, Tokyo</s2><s3>JPN</s3><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><inist:fA14 i1="07"><s1>Department of Neurology, Innsbruck Medical University</s1><s2>Innsbruck</s2><s3>AUT</s3><sZ>7 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><inist:fA14 i1="08"><s1>Departments of Clinical Pharmacology and Neurosciences, Clinical Investigation Center INSERM CIC9302 and INSERM UMR825, Toulouse University Hospital</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Marek, Kenneth" sort="Marek, Kenneth" uniqKey="Marek K" first="Kenneth" last="Marek">Kenneth Marek</name><affiliation><inist:fA14 i1="09"><s1>Institute for Neurodegenerative Disorders</s1><s2>New Haven, Connecticut</s2><s3>USA</s3><sZ>9 aut.</sZ></inist:fA14></affiliation></author></analytic><series><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno><imprint><date when="2010">2010</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Nervous system diseases</term><term>Parkinson disease</term><term>Pramipexole</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term><term>Pathologie du système nerveux</term><term>Pramipexole</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Perhaps the most important unmet need in Parkinson's disease (PD) is the ability to slow or prevent progression of the neurodegeneration that underlies the motor and nonmotor features of this disorder. Pramipexole, a dopamine agonist used for the symptomatic treatment of PD, has demonstrated neuroprotective properties in laboratory studies. The PRamipexole On Underlying Disease (PROUD) study is a randomized, double-blind clinical trial evaluating the ability of pramipexole to modify disease progression using a delayed-start design. PD patients (n = 535) with mean age 62.5 years, mean duration since diagnosis of 4.4 months, and mean total Unified Parkinson's disease Rating Scale (UPDRS) score of 24.5 were recruited. In Phase I, patients were randomly assigned to be titrated to 1.5 mg pramipexole or placebo and maintained on study drug for 6-9 months. In Phase II, all patients were titrated to 1.5 mg pramipexole and maintained on study drug until the end of the study at 15 months. No rescue medication was allowed in the protocol. The primary endpoint is the change in total UPDRS score (parts I-III) from baseline to 15 months. A range of secondary endpoints separately assess UPDRS subscales, quality of life, depression, and impulse control disorders. A sub-study examined dopamine transporter uptake scans at baseline and 15 months. The results of PROUD will provide insight into the potential for early versus delayed treatment with pramipexole to modify motor outcome at 15 months in recently diagnosed PD patients.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0></fA01><fA03 i2="1"><s0>Mov. disord.</s0></fA03><fA05><s2>25</s2></fA05><fA06><s2>11</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Rationale for Delayed-Start Study of Pramipexole in Parkinson's Disease: The PROUD Study</s1></fA08><fA11 i1="01" i2="1"><s1>SCHAPIRA (Anthony H. V.)</s1></fA11><fA11 i1="02" i2="1"><s1>ALBRECHT (Stefan)</s1></fA11><fA11 i1="03" i2="1"><s1>BARONE (Paolo)</s1></fA11><fA11 i1="04" i2="1"><s1>COMELLA (Cynthia L.)</s1></fA11><fA11 i1="05" i2="1"><s1>MCDERMOTT (Michael P.)</s1></fA11><fA11 i1="06" i2="1"><s1>MIZUNO (Yoshikuni)</s1></fA11><fA11 i1="07" i2="1"><s1>POEWE (Werner)</s1></fA11><fA11 i1="08" i2="1"><s1>RASCOL (Olivier)</s1></fA11><fA11 i1="09" i2="1"><s1>MAREK (Kenneth)</s1></fA11><fA14 i1="01"><s1>Department of Clinical Neurosciences, Institute of Neurology, University College London</s1><s2>London</s2><s3>GBR</s3><sZ>1 aut.</sZ></fA14><fA14 i1="02"><s1>Boehringer Ingelheim GmbH, CD Medical Affairs CNS</s1><s2>Ingelheim</s2><s3>DEU</s3><sZ>2 aut.</sZ></fA14><fA14 i1="03"><s1>Department of Neurological Sciences, University of Naples, Federico II and IDC-Hermitage-Capodimonte</s1><s2>Naples</s2><s3>ITA</s3><sZ>3 aut.</sZ></fA14><fA14 i1="04"><s1>Department of Neurological Sciences, Rush University Medical Center</s1><s2>Chicago, Illinois</s2><s3>USA</s3><sZ>4 aut.</sZ></fA14><fA14 i1="05"><s1>Department of Biostatistics and Computational Biology, University of Rochester Medical Center</s1><s2>Rochester, New York</s2><s3>USA</s3><sZ>5 aut.</sZ></fA14><fA14 i1="06"><s1>Department of Neurology, Juntendo University School of Medicine</s1><s2>Bunkyo-ku, Tokyo</s2><s3>JPN</s3><sZ>6 aut.</sZ></fA14><fA14 i1="07"><s1>Department of Neurology, Innsbruck Medical University</s1><s2>Innsbruck</s2><s3>AUT</s3><sZ>7 aut.</sZ></fA14><fA14 i1="08"><s1>Departments of Clinical Pharmacology and Neurosciences, Clinical Investigation Center INSERM CIC9302 and INSERM UMR825, Toulouse University Hospital</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>8 aut.</sZ></fA14><fA14 i1="09"><s1>Institute for Neurodegenerative Disorders</s1><s2>New Haven, Connecticut</s2><s3>USA</s3><sZ>9 aut.</sZ></fA14><fA20><s1>1627-1632</s1></fA20><fA21><s1>2010</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>20953</s2><s5>354000192608100140</s5></fA43><fA44><s0>0000</s0><s1>© 2010 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>33 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>10-0413282</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Movement disorders</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Perhaps the most important unmet need in Parkinson's disease (PD) is the ability to slow or prevent progression of the neurodegeneration that underlies the motor and nonmotor features of this disorder. Pramipexole, a dopamine agonist used for the symptomatic treatment of PD, has demonstrated neuroprotective properties in laboratory studies. The PRamipexole On Underlying Disease (PROUD) study is a randomized, double-blind clinical trial evaluating the ability of pramipexole to modify disease progression using a delayed-start design. PD patients (n = 535) with mean age 62.5 years, mean duration since diagnosis of 4.4 months, and mean total Unified Parkinson's disease Rating Scale (UPDRS) score of 24.5 were recruited. In Phase I, patients were randomly assigned to be titrated to 1.5 mg pramipexole or placebo and maintained on study drug for 6-9 months. In Phase II, all patients were titrated to 1.5 mg pramipexole and maintained on study drug until the end of the study at 15 months. No rescue medication was allowed in the protocol. The primary endpoint is the change in total UPDRS score (parts I-III) from baseline to 15 months. A range of secondary endpoints separately assess UPDRS subscales, quality of life, depression, and impulse control disorders. A sub-study examined dopamine transporter uptake scans at baseline and 15 months. The results of PROUD will provide insight into the potential for early versus delayed treatment with pramipexole to modify motor outcome at 15 months in recently diagnosed PD patients.</s0></fC01><fC02 i1="01" i2="X"><s0>002B17</s0></fC02><fC02 i1="02" i2="X"><s0>002B17G</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du système nerveux</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Pramipexole</s0><s2>NK</s2><s2>FR</s2><s5>09</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Pramipexole</s0><s2>NK</s2><s2>FR</s2><s5>09</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Pramipexol</s0><s2>NK</s2><s2>FR</s2><s5>09</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du système nerveux central</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0><s5>40</s5></fC07><fN21><s1>270</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard><server><NO>PASCAL 10-0413282 INIST</NO><ET>Rationale for Delayed-Start Study of Pramipexole in Parkinson's Disease: The PROUD Study</ET><AU>SCHAPIRA (Anthony H. V.); ALBRECHT (Stefan); BARONE (Paolo); COMELLA (Cynthia L.); MCDERMOTT (Michael P.); MIZUNO (Yoshikuni); POEWE (Werner); RASCOL (Olivier); MAREK (Kenneth)</AU><AF>Department of Clinical Neurosciences, Institute of Neurology, University College London/London/Royaume-Uni (1 aut.); Boehringer Ingelheim GmbH, CD Medical Affairs CNS/Ingelheim/Allemagne (2 aut.); Department of Neurological Sciences, University of Naples, Federico II and IDC-Hermitage-Capodimonte/Naples/Italie (3 aut.); Department of Neurological Sciences, Rush University Medical Center/Chicago, Illinois/Etats-Unis (4 aut.); Department of Biostatistics and Computational Biology, University of Rochester Medical Center/Rochester, New York/Etats-Unis (5 aut.); Department of Neurology, Juntendo University School of Medicine/Bunkyo-ku, Tokyo/Japon (6 aut.); Department of Neurology, Innsbruck Medical University/Innsbruck/Autriche (7 aut.); Departments of Clinical Pharmacology and Neurosciences, Clinical Investigation Center INSERM CIC9302 and INSERM UMR825, Toulouse University Hospital/Toulouse/France (8 aut.); Institute for Neurodegenerative Disorders/New Haven, Connecticut/Etats-Unis (9 aut.)</AF><DT>Publication en série; Niveau analytique</DT><SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2010; Vol. 25; No. 11; Pp. 1627-1632; Bibl. 33 ref.</SO><LA>Anglais</LA><EA>Perhaps the most important unmet need in Parkinson's disease (PD) is the ability to slow or prevent progression of the neurodegeneration that underlies the motor and nonmotor features of this disorder. Pramipexole, a dopamine agonist used for the symptomatic treatment of PD, has demonstrated neuroprotective properties in laboratory studies. The PRamipexole On Underlying Disease (PROUD) study is a randomized, double-blind clinical trial evaluating the ability of pramipexole to modify disease progression using a delayed-start design. PD patients (n = 535) with mean age 62.5 years, mean duration since diagnosis of 4.4 months, and mean total Unified Parkinson's disease Rating Scale (UPDRS) score of 24.5 were recruited. In Phase I, patients were randomly assigned to be titrated to 1.5 mg pramipexole or placebo and maintained on study drug for 6-9 months. In Phase II, all patients were titrated to 1.5 mg pramipexole and maintained on study drug until the end of the study at 15 months. No rescue medication was allowed in the protocol. The primary endpoint is the change in total UPDRS score (parts I-III) from baseline to 15 months. A range of secondary endpoints separately assess UPDRS subscales, quality of life, depression, and impulse control disorders. A sub-study examined dopamine transporter uptake scans at baseline and 15 months. The results of PROUD will provide insight into the potential for early versus delayed treatment with pramipexole to modify motor outcome at 15 months in recently diagnosed PD patients.</EA><CC>002B17; 002B17G</CC><FD>Maladie de Parkinson; Pathologie du système nerveux; Pramipexole</FD><FG>Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central</FG><ED>Parkinson disease; Nervous system diseases; Pramipexole</ED><EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG><SD>Parkinson enfermedad; Sistema nervioso patología; Pramipexol</SD><LO>INIST-20953.354000192608100140</LO><ID>10-0413282</ID></server></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000956 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000956 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:10-0413282
|texte= Rationale for Delayed-Start Study of Pramipexole in Parkinson's Disease: The PROUD Study
}}
| This area was generated with Dilib version V0.6.23. |  |